MY CONTENT

The ASNR Standards and Guidelines Committee reviewed new research evidence on GBCA safety and its relevance to current MRI contrast administration guidelines for patients with CKD. The recommendations for CKD patients are that there is no longer a need to withhold group II GBCAs when medically indicated for diagnosis and that it is not necessary to check renal function for these agents.